RNS Number : 0458S Renalytix PLC 07 March 2023 Issue of Shares LONDON and SALT LAKE CITY , March 7, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 166,674 new ordinary shares of £0.0025 each in the capital of the
RNS Number : 6255P Renalytix PLC 10 February 2023 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of
RNS Number : 6203P Renalytix PLC 10 February 2023 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing LONDON and SALT LAKE CITY , February 10, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) confirms that further to the announcement on February 8 of a c.
LONDON and SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14-16, 2023 in Snowbird, Utah.
RNS Number : 3776P Renalytix PLC 09 February 2023 Renalytix to Participate in the BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference LONDON and SALT LAKE CITY , February 9, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will be
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.
RNS Number : 2418P Renalytix PLC 08 February 2023 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES
Award for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney disease LONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of
RNS Number : 8999N Renalytix PLC 26 January 2023 Renalytix plc (" Renalytix " or the " Company ") Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United States Award for consortium of industry,
Significant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney disease LONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA)
